BIOHIT'S ANNUAL REPORT 2009 HAS BEEN PUBLISHED
BIOHIT OYJ STOCK EXCHANGE ANNOUNCEMENT ON 21 APRIL 2010
BIOHIT'S ANNUAL REPORT 2009 HAS BEEN PUBLISHED
The Annual Report 2009 is now available in Finnish and English on Biohit's web
site at www.biohit.com/investors. The Annual Report includes the previously
published financial statements, the report of the Board of Directors and the
auditors' report, as well as the annual summary for 2009.
Hardcopies of the Annual Report may be ordered from Biohit, via telephone:
+358-9-773 861, via email comms@biohit.com or via the order form at Biohit's
website.
Josefin Hoviniemi
Marketing & Communications Director
Biohit Oyj
Distribution:
NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com
About Biohit Oyj
Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on
the global market. Biohit's operations are based on a goal-oriented and
long-term innovation and patenting strategy.
Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work as
well as diagnostic tests for the early detection and prevention of diseases of
the gastrointestinal tract.
Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips as
well as pipette maintenance and calibration services for research institutions,
healthcare and industrial laboratories.
The diagnostics business comprises products and analysis systems for the early
diagnosis of gastrointestinal diseases, such as the blood-sample based
GastroPanel examinations for the diagnosis of stomach illnesses and associated
risks, quick tests for the diagnosis of lactose intolerance and H. pylori
infection in connection with gastroscopy, and the ColonView examination for the
early detection of intestinal bleeding that indicates a risk of colorectal
cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic
stomachs.
The Biohit Group employs around 370 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA, as well as a representative office in
Singapore. Additionally, Biohit's products are sold by approximately 450
distributors in 70 countries.
Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small
cap/Healthcare since 1999.
Read more at www.biohit.com
